Introduction
Although astrocytes have traditionally been considered to be electrically inexcitable, studies since the 1990s have demonstrated that these cells express voltage-gated sodium channels (VGSCs) [1] , including the isotype Na v 1.5 [2, 3] . These studies suggest that expression of VGSCs in rodent astrocytes is a dynamic process, changing with response to injury, age, and exposure to the extracellular milieu [4] [5] [6] . Notably, Black et al. [7] demonstrated the presence of Na v 1.5 in human scarring astrocytes in situ within acute and chronic multiple sclerosis (MS) lesions and surrounding cerebrovascular accidents and central nervous system (CNS) tumors, suggesting a commonality of upregulated astrocytic Na v 1.5 following CNS tissue injury.
Despite the well-characterized expression of VGSCs in both rodent and human astrocytes, the functional role of these VGSCs has remained elusive. Astrocytes have multiple functions in the CNS, including ionic homeostasis and neuronal support. Sontheimer et al. [8] suggested that VGSCs provide a route for [Na + ] i influx necessary for the Na + /K + -ATPase function within astrocytes and thus participate in K + homeostasis in the CNS. Astrocytes are also important contributors to the response of the CNS to neuroinflammatory pathologies, including MS. One such response is reactive astrogliosis, which can have both beneficial and detrimental effects on the CNS [9] . Severe forms of astrogliosis involve formation of a scar that is long-lasting and can inhibit the regeneration of injured neurons [10] . Recent work has shown that Na v 1.5 plays an important role in an in-vitro model of glial injury by triggering reverse-mode operation of the Na + -Ca 2 + exchanger (NCX) [3] . These results suggest that Na v 1.5 and NCX are potential targets for modulation of astrogliosis after injury through their effect on [Ca 2 + ] i .
Given the dynamic expression of VGSCs in rodent astrocytes [4] [5] [6] , the upregulation of Na v 1.5 in human scarring astrocytes [7] , and the functional role of Na v 1.5 in glial scar formation in vitro [3] , we examined the temporal dynamics of Na v 1.5 expression in scarring astrocytes in neuroinflammatory pathologies, with respect to disease severity and periods of relapse/remission. Here, we investigate the expression of astrocytic Na v 1.5 in two mouse models of MS, monophasic experimental autoimmune encephalomyelitis (EAE) and chronic-relapsing EAE (CR EAE). We show that Na v 1.5 upregulation correlates with disease severity and that Na v 1.5 expression in astrocytes is modulated in parallel with periods of disease and remission.
Materials and methods

Induction of encephalomyelitis
Experiments were carried out in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals; all animal protocols were approved by the Institutional Animal Care and Use Committee of VA Connecticut Healthcare System, West Haven, Connecticut. C57BL/6 (Harlan, Indianapolis, Indiana, USA) and Biozzi (Harlan Sera-Lab Ltd, Loughborough, UK) mice that were between 6 and 10 weeks of age were injected subcutaneously in the flank with 200 μl of an emulsion of 300 μg of rat myelin oligodendrocyte glycoprotein (MOG) 35-55 peptide (W. M. Keck Biotechnology Resource Center, Yale University, New Haven, Connecticut, USA) in incomplete Freund's adjuvant (Sigma, St Louis, Missouri, USA) supplemented with 500 μg of Mycobacterium tuberculosis H37Ra (Difco, Detroit, Michigan, USA), as described previously [11] . The MOG injection, with mycobacterium-supplemented incomplete Freund's adjuvant, was repeated in the contralateral flank 1 week later. The mice also received an intraperitoneal injection of 250 ng pertussis toxin (Sigma) in 200 μl PBS immediately after the first immunization with MOG and then again 48 h later. In agreement with previous descriptions, the C57BL/6 mice developed a monophasic clinical course, whereas the Biozzi mice exhibited a CR clinical phenotype. Control animals received the same injections, with the omission of MOG. A total of 18 C57BL/6 and 20 Biozzi mice were injected.
Clinical assessment
Immunized mice were observed daily and scored on a clinical scale from 0 to 6, with increasing clinical score reflecting clinical worsening as follows: 1, flaccid tail; 2, abnormal righting reflex and/or abnormal gait in the absence of weakness; 3, partial hindlimb paralysis; 4, complete hindlimb paralysis; 5, moribund; and 6, death [12] . We applied the scale in 0.5 increments. To characterize the clinical course of CR EAE, the initial episode was defined as a clinical score of 2.0 or higher for two or more consecutive days. Subsequent relapses were identified by clinical score increases of at least 1.0, and defined remissions were identified by clinical score decreases of at least 1.0. To estimate the overall clinical burden of disease in CR EAE, the mean clinical score was determined by averaging the clinical scores on all of the sick days for each animal.
Tissue collection
Mice were killed at varying relapse-remission phases and lengths of disease (range 9-59 days) from the date of induction of EAE. Mice were anesthetized with ketamine/xylazine (80/5 mg/kg intraperitoneally) and perfused through the heart with PBS and then with 4% paraformaldehyde in 0.14 M Sorensen's phosphate buffer. Spinal cords and brains were carefully excised, cryoprotected with 30% sucrose in PBS, and frozen.
Immunocytochemistry
Twelve-micrometer transverse sections of L1-L2 spinal cords and sagittal sections of the cortices (bregma 0-1 mm, M2) were cut and incubated with primary antibodies [mouse anti-glial fibrillary acidic protein (GFAP), 1 : 1000, catalog #SMI-22R; Covance, Princeton, New Jersey, USA; rabbit anti-Na v 1.5, 1 : 100, catalog #ASC-013; Alomone, Jerusalem, Israel] overnight at 4°C on a rotating shaker. Sections were rinsed three times with PBS and incubated with secondary antibodies [donkey anti-mouse immunoglobulin G-Alexa Fluor 488, 1 : 1000, cat #P-11065; Invitrogen, Grand Island, New York, USA; donkey anti-rabbit immunoglobulin G Cy3, 1 : 500, cat #711-165-152; Jackson, West Grove, Pennsylvania, USA] overnight. Slides were rinsed with PBS and coverslips were mounted with Aqua Poly mount (Polysciences, Warrington, Pennsylvania, USA). Control experiments were performed with the omission of the primary antibodies, and only background labeling was observed.
Data acquisition and analysis
Multiple images of control, C57BL/6, and Biozzi tissues were accrued with a Nikon C1si confocal microscope (Nikon USA, Melville, New York, USA) operating under identical gain settings with frame lambda (sequential) mode and saturation indicator activated to prevent possible bleed-through between channels. For quantitative analysis of Na v 1.5, NIS Elements software (Nikon USA, Melville, New York, USA) was utilized. For C57BL/6 animals (monophasic EAE), high-magnification images of astrocytes in the anterolateral white matter in the L1-L2 region of the spinal cord were selected for analysis. Regions of interest for mean RGB intensity analysis were created by manually outlining individual astrocytes on the basis of GFAP staining. Multiple high-magnification images for each animal were taken, quantified, and averaged. For description of astrocytic expression of Na v 1.5 in the motor cortex, high-magnification images of astrocytes in the parasagittal motor cortex (bregma 0-1 mm, M2) were obtained.
For Biozzi animals (CR EAE), low-magnification images of the L1-L2 region of the spinal cord were analyzed. To quantify astrocytic Na v 1.5 levels, thresholds were set at the same value for all images by creating a binary layer based on visible GFAP staining in control tissues.
Subsequently, regions of interest were manually defined in anterolateral white matter, and the RGB mean intensity of the region of interest was extracted within the binary layer. Multiple low-magnification images for each animal were taken, quantified, and averaged. One of the twenty Biozzi EAE animals was excluded secondary to poor tissue quality due to severity of disease. Images were composed and processed to enhance contrast in the figures in Adobe Photoshop, with identical settings for the different conditions.
Statistical methods
Clinical scores for C57/B6 animals (monophasic EAE) were represented by the clinical score on the day of euthanasia. Clinical scores for Biozzi animals (CR EAE) were computed by averaging the clinical scores on each day of disease, to estimate the mean overall disease severity. To assess the correlation between Na v 1.5 immunolabeling and animal clinical status, correlation coefficients (Spearman's for normally distributed data; Pearson's for nonparametric data) and two-tailed P-values were calculated with GraphPad Prism (GraphPad Software, La Jolla, California, USA). Data were normalized to percent fluorescence compared with control animals.
Results
Astrocytes do not show sodium channel Na v 1.5 immunolabeling above background levels in control human brains, but show robust Na v 1.5 immunofluorescence within acute and chronic MS lesions [7] . To examine the temporal pattern of Na v 1.5 expression in astrocytes and the relationship of the degree of Na v 1.5 expression with disease severity in a murine model of MS, we examined tissue from mice with acute monophasic and CR experimental autoimmune EAE.
Spinal cord and motor cortex astrocytes in mice with monophasic encephalomyelitis exhibit upregulated Na v 1.5 expression Astrocytes within the anterolateral white matter of the spinal cord of control C57BL/6 mice did not show Na v 1.5 immunolabeling above background levels (Fig. 1a) . In contrast, the progression of clinical severity in C57BL/6 mice with monophasic EAE was associated with increasing levels of Na v 1.5 immunofluorescence (Fig. 1b) . Na v 1.5 labeling was detectable at low levels above the background level in astrocytes from mice with EAE with a clinical score of 2.5 (abnormal righting reflex/ mild weakness in hindlimbs), whereas robust Na v 1.5 reactivity was generally exhibited by astrocytes in mice with EAE with clinical scores greater than 4.0 (complete hindlimb paralysis).
As shown in Fig. 1b , quantification of Na v 1.5 immunofluorescence in astrocytes within spinal cord anterolateral white matter of mice with monophasic EAE yielded a positive correlation between the mean astrocytic Na v 1.5 signal and the clinical score (R = 0.7131, P = 0009, n = 18 animals), consistent with increased expression of Na v 1.5 within astrocytes as mice with monophasic EAE exhibited increasing disease severity.
The enhancement of Na v 1.5 immunofluorescence in astrocytes with increasing clinical score was also manifested in astrocytes within different regions of the CNS. For example, astrocytes within the motor cortex of mice with monophasic EAE exhibited increased Na v 1.5 immunolabeling with increasing disease severity, as observed in Fig. 1c .
Spinal cord astrocytes in mice with chronic-relapsing encephalomyelitis show upregulated Na v 1.5 expression
To assess the disease severity in Biozzi mice with CR EAE, the total of the clinical scores on each day after the onset of the disease (clinical score > 1.0) until euthanasia was calculated and then divided by the number of days in the disease state to yield the mean clinical score, reflective of overall disease burden. As exemplified in Fig. 2a , astrocytes within spinal cord anterolateral white matter exhibited enhanced Na v 1.5 immunofluorescence with increasing mean clinical score. Quantification of the mean astrocytic Na v 1.5 signal intensity yielded a positive correlation (R = 0.7541, P = 0.0002, n = 19) with increasing mean clinical score (Fig. 2b) .
We also determined whether the level of Na v 1.5 immunolabeling in astrocytes in Biozzi mice with CR EAE was altered in remitting and relapsing phases of the disease. As shown in Fig. 3a , MOG inoculation of Biozzi mice induced a relapsing-remitting form of EAE, with mean clinical scores of ∼ 2.5 in the first episode and first relapse and ∼ 1.8 and ∼ 2.0 in the first and second remissions, respectively. Astrocytes within spinal cord anterolateral white matter showed Na v 1.5 immunofluorescent signals that paralleled the relapsing-remitting clinical course (Fig. 3b ). Quantification of Na v 1.5 immunofluorescence in astrocytes in the CR phases is provided in Fig. 3c and is consistent with an upregulation of Na v 1.5 in astrocytes in the first episode that was attenuated in the first remission, further upregulated in the first episode, and again attenuated in the second remission.
Discussion
Previous studies have shown that rodent astrocytes express VGSCs (for review see Sontheimer et al. [1] ), including Na v 1.5 sodium channels [2, 3] . Black et al. [2] showed the presence of Na v 1.5 mRNA and protein in rodent astrocytes in vitro and in situ, and Black et al. [7] showed upregulated expression of Na v 1.5 in astrocytes associated with acute and chronic MS lesions, new and old stroke lesions, and CNS tumors, including gliomas and metastatic carcinomas. However, the temporal sequence of Na v 1.5 expression in activated astrocytes has yet to be established. Here, we examine the expression of astrocytic Na v 1.5 in different phases of monophasic and CR EAE models of MS. We show that Na v 1.5 upregulation in astrocytes is correlated with disease severity of the mice, as indicated by clinical score. The low level of Na v 1.5 expression in astrocytes of control animals suggests that Na v 1.5 upregulation is a part of the biological response of astrocytes to CNS insult. The expression of Na v 1.5, which is tetrodotoxin (TTX) resistant [13] in astrocytes, appears to be a dynamic process, changing with the age of the animal and culture conditions, exposure to extracellular factors, and response to injury [3] [4] [5] [6] . MacFarlane and Sontheimer [4] described a shift from TTX-sensitive sodium currents to TTXresistant sodium currents with properties ascribed to Na v 1.5 in rodent astrocytes in an in-vitro model of glial injury. Our finding that Na v 1.5 expression in astrocytes is modulated in parallel with the clinical course of the animal is consistent with the notion that Na v 1.5 is regulated temporally in astrocytes in response to neuroinflammation.
Astrocytes perform multiple functions in the CNS, and the functional roles of VGSCs in astrocytes is incompletely understood, although studies have provided certain insight (for review of noncanonical roles of VGSCs in astrocytes and other nonexcitable cell types, see Black and Waxman [14] ). It has been shown that VGSCs in astrocytes are localized to the plasma membrane, where they are capable of producing sodium currents [15] . A standing Na + influx in astrocytes is critical for Na + /K + -ATPase activity, and Sontheimer et al. [8] proposed that VGSCs channels provide a pathway for Na + to enter the cell to maintain [Na + ] i at levels necessary for Na + /K + -ATPase activity. This action, in turn, supports the regulation of ionic homeostasis in the CNS, with particular regard to K + fluxes. Inglese et al. [16] demonstrated through 23 Na MRI that sodium concentrations are elevated in acute and chronic MS lesions when compared with normal-appearing white matter, providing a possible clinical correlate to the suggestion of Black et al. [7] that upregulation of Na v 1.5 may serve as a compensatory mechanism to support ionic homeostasis mediated by Na + /K + -ATPase activity in areas of CNS damage. In addition to other functions in the CNS, astrocytes are prominent participants in the response to inflammatory insults through the process of reactive astrogliosis, which occurs following injury in many CNS pathologies, including MS. Although activated astrocytes can exert beneficial and detrimental actions following CNS injury [9] , recent work has linked proinflammatory effects of activated astrocytes as critical contributors to the inflammatory response in EAE [17] . In addition, severe forms of astrogliosis are associated with the formation of a glial scar, which is often persistent and can impede neuronal regeneration after injury [10] .
Accumulating evidence indicates a role of [Na + ] i transients in astroglial excitability and cellular homeostasis, with a prominent mechanism involving the linkage of transmembrane movements of Na + and Ca 2 + through the reverse mode of the NCX [18] . The reversal potential of NCX in astrocytes is set at levels close to the resting membrane potential [19] ; therefore, NCX can quickly switch into the reverse mode in response to small [Na + ] i increases and/or depolarization [18, 20] , as would be seen with VGSC activation, causing an increase in [Ca 2 + ] i .
Recent work has shown that Na v 1.5 plays an important role in an in-vitro model of glial injury through reverse action of NCX [3] . Astrocyte wound closure after mechanical injury is attenuated by pharmacological treatment with TTX and KB-R7943 (at a dose that selectively blocks reverse Na + /Ca 2 + exchange) and by knockdown of Na v 1.5 mRNA. The robust [Ca 2 + ] i response seen in astrocytes after mechanical injury, which is involved in the pathways leading to astrogliosis [21] , is also attenuated by TTX, KB-R7943, and Na v 1.5 knockdown [3] . The upregulation of Na v 1.5 in astrocytes in situ in animals with monophasic and CR EAE in correlation with increasing disease severity is consistent with these in-vitro results. Together, these findings support the suggestion that Na v 1.5 may be a potential target for modulation of astrogliosis after injury through effects on [Ca 2 + ] i .
There is a growing body of evidence detailing the favorable effect of sodium channel blockade in animal models of neurological diseases, including EAE. Several sodium channel blockers have been studied, including phenytoin [22, 23] , lamotrigine [24] , carbamazepine [23] , safinamide, and flecainide [25] . It is noteworthy that flecainide, a Class Ic cardiac antiarrhythmic, has strong state-dependent effects on Na v 1.5 [26] . The present findings, along with others detailed here, raise the possibility that attenuation of reactive astrogliosis could contribute to the improved outcomes seen on sodium channel blockade. This study lends further insight into the suggestion that Na v 1.5 can play a role in the response of astrocytes to neuroinflammatory pathologies, identifying this sodium channel as an attractive potential therapeutic target for modulating reactive astrogliosis in vivo.
